Screening detected NPC in 0.96% (199/100,000 person-years), 80% T1 stage at diagnosis; EBV-EA IgA showed 94.6% specificity & 15.2% PPV, outperforming VCA IgA and cf-EBV DNA; rising EA IgA titers preceded diagnosis. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.